FDA approves limited trial to study CDX-1135
Kidneeds is a not-for-profit corporation dedicated to finding a cure for Dense Deposit Disease (DDD).
DDD, previously called MPGN2, is caused by dysregulation of the alternative pathway of complement. About half of people with DDD progress to end stage renal failure disease (ESRD) within 10 years of diagnosis. Transplant recipients face disease recurrence in their allografts.
Kidneeds' mission is to CURE DDD by stimulating research by funding grants to scientists to study DDD.
Kidneeds is also an educational resource for patients and for physicians.
Patients and their families can help us learn more about DDD by completing the:
This survey collects epidemiological data on persons with DDD and other types of kidney disease.
FDA approves limited trial to study CDX-1135
"FDA evaluation of this drug (CDX-1135) is a major milestone for me and for all DDD patients. It is paving a path to new possibilities and options for treating this dreadful disease. I thank everyone who has been there with us, all who are celebrating this news, and those who are as excited to see where we are going as I am! Thank you to everyone who has helped make this day happen for me and for all of us with DDD!” – Jenna Smith
CDX-1135 is a drug that is under evaluation as the first disease-specific therapy for DDD. For information on this FDA-approved study visit ClinicalTrials.gov.
NOTICE: Kidneeds is not in any way associated with http://www.kidneeds.com/ or its operator, St. Mary’s Healthcare System for Children, Inc.
